Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel D Banister

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
CNS Drugs|August 6, 2015
The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophreniaCorinne Beinat, Samuel D Banister, Marco Herrera, et al.
ACS Chemical Neuroscience|January 29, 2019
Dark Classics in Chemical Neuroscience: Δ<sup>9</sup>-TetrahydrocannabinolSamuel D Banister, Jonathon C Arnold, Mark Connor, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2012
A σ(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs)Samuel D Banister, Miral Manoli, Munikumar Reddy Doddareddy, et al.
Bioorganic & Medicinal Chemistry|August 29, 2013
N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effectsSamuel D Banister, Miral Manoli, Melissa L Barron, et al.
Pharmacology Research & Perspectives|February 27, 2020
Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonistsShivani Sachdev, Samuel D Banister, Marina Santiago, et al.
Pharmacology Research & Perspectives|November 29, 2023
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB<sub>2</sub> receptorMonica Patel, Natasha L Grimsey, Samuel D Banister, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2011
Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel σ1 receptor PET imaging agentIman A Moussa, Samuel D Banister, Nicolas Giboureau, et al.
Biochemical Pharmacology|February 14, 2024
Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB<sub>1</sub> receptorBeth Ryalls, Monica Patel, Eric Sparkes, et al.
Clinical Toxicology (Philadelphia, Pa.)|September 2, 2017
Synthetic cannabinoid "Black Mamba" infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN CohortNicklaus Brandehoff, Axel Adams, Kyle McDaniel, et al.
The New England Journal of Medicine|December 16, 2016
"Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New YorkAxel J Adams, Samuel D Banister, Lisandro Irizarry, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
CNS Drugs|August 6, 2015
The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophreniaCorinne Beinat, Samuel D Banister, Marco Herrera, et al.
ACS Chemical Neuroscience|January 29, 2019
Dark Classics in Chemical Neuroscience: Δ<sup>9</sup>-TetrahydrocannabinolSamuel D Banister, Jonathon C Arnold, Mark Connor, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2012
A σ(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs)Samuel D Banister, Miral Manoli, Munikumar Reddy Doddareddy, et al.
Bioorganic & Medicinal Chemistry|August 29, 2013
N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effectsSamuel D Banister, Miral Manoli, Melissa L Barron, et al.
Pharmacology Research & Perspectives|February 27, 2020
Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonistsShivani Sachdev, Samuel D Banister, Marina Santiago, et al.
Pharmacology Research & Perspectives|November 29, 2023
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB<sub>2</sub> receptorMonica Patel, Natasha L Grimsey, Samuel D Banister, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2011
Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel σ1 receptor PET imaging agentIman A Moussa, Samuel D Banister, Nicolas Giboureau, et al.
Biochemical Pharmacology|February 14, 2024
Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB<sub>1</sub> receptorBeth Ryalls, Monica Patel, Eric Sparkes, et al.
Clinical Toxicology (Philadelphia, Pa.)|September 2, 2017
Synthetic cannabinoid "Black Mamba" infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN CohortNicklaus Brandehoff, Axel Adams, Kyle McDaniel, et al.
The New England Journal of Medicine|December 16, 2016
"Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New YorkAxel J Adams, Samuel D Banister, Lisandro Irizarry, et al.
Pageof 9